| Entry |
|
|---|
| Name |
Sacituzumab govitecan (USAN/INN);
Sacituzumab govitecan-hziy;
Trodelvy (TN) |
|---|
| Product |
|
|---|
| Remark |
|
|---|
| Efficacy |
Antineoplastic, Topoisomerase I inhibitor |
|---|
| Disease |
Breast cancer (triple negative) [DS: H00031] |
|---|
| Comment |
Antibody-drug conjugate
|
|---|
| Target |
|
|---|
| Brite |
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Other cell surface molecules
Other
TACSTD2 (TROP2)
D10985 Sacituzumab govitecan (USAN/INN) <US>
Enzymes
Isomerases (EC5)
DNA topoisomerase
TOP1
D10985 Sacituzumab govitecan (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10985
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10985
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D10985
|
|---|
| Other DBs |
|
|---|
